Working… Menu
Trial record 67 of 185 for:    RET

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01226056
Recruitment Status : Suspended (toxicity (protocol amendment under approval))
First Posted : October 21, 2010
Last Update Posted : October 21, 2010
Information provided by:
Southern Europe New Drug Organization

Brief Summary:

Sorafenib is an oral multikinase inhibitor and among its targets are several RTKs involved in tumor genesis (Raf, Flt-3, c-Kit and RET) and angiogenesis (VEGFR1, 2 and 3 and PDGFRß). Therefore sorafenib inhibits tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling.

RAD001 is a novel derivative of rapamycin. It selectively inhibits mTOR directly blocking tumor cells by preventing tumor cell growth and proliferation and indirectly by inhibiting angiogenesis (via potent inhibition of the HIF-1 and consequently VEGF production).

Targeting mTOR in combination with sorafenib might lead to more profound effects on tumor cell biology than could be achieved through individual targeting of some proteins.

New drugs have often met only limited success since not always target pathways responsible for tumor development and growth are targeted. To overcome this problem, the specific pathways targeted by the investigators two drugs will be analyzed in each single patient before the inclusion.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: RAD001 in combination with sorafenib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets
Study Start Date : March 2009
Estimated Primary Completion Date : September 2012
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RAD001 in combination with sorafenib Drug: RAD001 in combination with sorafenib

Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.

The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).

Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.

Other Names:
  • RAD001 (Everolimus)
  • Sorafenib (Nexavar®)

Primary Outcome Measures :
  1. Phase I: Maximum Tolerated Dose (MTD) [ Time Frame: 6 weeks ]
    The maximum tolerated dose (MTD) is defined as the dose in which 2 of 3 or 2 of 6 patients experience a DLT. The Recommended Dose is identified as one dose level below the MTD.

  2. Phase II: PFS (Progression Free survival) rate [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Phase I: Pharmacokinetics profile of both drugs [ Time Frame: 6 weeks ]
  2. Phase II: overall survival [ Time Frame: 15 months ]
  3. Tumor response [ Time Frame: every 8 weeks ]
    Evaluated according to RECIST criteria

  4. Objective Response Rate (ORR) [ Time Frame: 15 months ]
  5. Incidence and severity of AEs [ Time Frame: 36 months ]
    graded according to CTCAE criteria v3.0

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with progressive disease of advanced solid tumours judged non suitable for standard treatment
  2. Biopsiable lesion or archive tissue not older than 1 year to assess the expression of:

    • phosphorylated AKT
    • phosphorylated p70S6
    • RKIP (Raf Kinase Inhibitor Protein)
    • phosphorylated ERK1/2 The presence of at least one of the previous targets will be mandatory for patient enrolment
  3. At least 1 uni-dimensional measurable lesion according to modified RECIST
  4. Life expectancy of at least 12 weeks
  5. Age ≥ 18 years old
  6. ECOG Performance Status of 0 or 1
  7. Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:

    • Haemoglobin ≥9.0 g/dL (5.6 mmol/L)
    • Absolute neutrophil count (ANC)≥1.5 x 109/L
    • Platelet count ≥100 x 109/L
    • Total bilirubin ≤1.5 x upper limit of normal (ULN)
    • ALT and AST ≤2.5 x ULN (≤5 x ULN for patients with liver involvement of their cancer)
    • Alkaline phosphatase ≤4 x ULN
    • PT-INR/PTT <1.5 x ULN
    • Serum albumin levels ≥2.5 mg/dl
    • Serum creatinine ≤1.5 x ULN
  8. HBV/HCV testing in the 2 weeks before treatment start in specific categories of patient with hepatitis B and C risk factors and in additional patients at the discretion of the investigators according to guidelines in Appendix 6.
  9. All fertile patients must use adequate contraception while on study and for three subsequent months
  10. Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to performing any study specific procedures

Exclusion Criteria:

  1. History of cardiac disease: congestive heart failure (NYHA II-IV), active coronary artery disease - CAD (MI more than 6 months prior to study entry is allowed), cardiac arrhythmias requiring antiarrhythmic therapy (betablockers or digoxin are permitted) or uncontrolled hypertension
  2. History of HIV infection or chronic hepatitis B or C
  3. Patients with NSCLC squamous histotype
  4. Recurrent hemoptysis or cerebrovascular accident within 12 months, or peripheral vascular disease with claudication on less than 1 block (about 150 metres), or history of clinically significant bleeding non-traumatic
  5. Deep venous thrombosis or pulmonary embolus within 1 year or ongoing need for full-dose oral or parenteral anticoagulation
  6. Clinically active infections (> Grade 2 NCI-CTC AE version 3.0)
  7. Evidence of CNS tumor metastases
  8. History of organ allograft
  9. Pre-existing thyroid abnormality where thyroid function cannot be maintained in the normal range by medication
  10. Serious, non-healing wound, ulcer, or bone fracture
  11. Second malignancies within the past 5 years (except for non - melanoma skin cancer and cervical carcinoma in situ)
  12. Pregnant or breast-feeding patients
  13. Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  14. Any condition that is unstable or could jeopardize the safety of the patient and his/her compliance in the study
  15. Patients unable to swallow oral medications
  16. Any malabsorption condition
  17. Prior treatment with sorafenib or m-TOR inhibitors
  18. Ongoing requirement for systemic corticosteroid medication or other immunosuppressants
  19. Radiotherapy within 3 weeks of start of study drug. Palliative radiotherapy is allowed. Major surgery within 4 weeks of study entry
  20. Radiotherapy involving > 30% of the active bone marrow
  21. Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
  22. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or planned during the study period
  23. Investigational drug therapy outside of this trial during or within 4 weeks of study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01226056

Layout table for location information
Istituto Europeo di Oncologia,
Milano, Italy, 20141
Sponsors and Collaborators
Southern Europe New Drug Organization
Layout table for investigator information
Study Chair: filippo De Braud, MD IEO, Milano (Italy)

Layout table for additonal information
Responsible Party: Scientific Director, SENDO Identifier: NCT01226056     History of Changes
Other Study ID Numbers: S075SORD01
First Posted: October 21, 2010    Key Record Dates
Last Update Posted: October 21, 2010
Last Verified: October 2010
Keywords provided by Southern Europe New Drug Organization:
advanced solid tumors
Sorafenib (Nexavar®)
RAD001 (everolimus)
tumor molecular targets
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action